We are excited to announce that Dr. Bradley Welling is searching for participants for his new study entitled “Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2,” which is being funded by NF Northeast.
The aim of this study is to explore possible treatments for NF2-associated schwannomas by testing the effect of direct injection of tumors in and just under the skin with doxycycline, a commonly used antibiotic. Doxycycline was selected because of its safety profile and also because of its anti-tumor role in a multitude of cancers and other disorders.
If successful, this study may introduce a novel direct treatment path for NF2 -associated schwannomas and potentially reduce the side effects of other treatments now being used to control tumor growth.
Dr. Welling is searching for participants who are 8 years of age and older with NF2-associated skin schwannomas between 0.5 cm and 4 cm in greatest diameter who are not on other drugs for NF2. For more information on this study, click HERE.
To learn more or inquire further, please contact:
Alyssa Brown, BS (Study Coordinator) at: Alyssa_Brown@meei.harvard.edu or by phone at 203-434-9763
D. Bradley Welling, MD, PhD (Principle Investigator) at Brad_Welling@meei.harvard.edu or by phone at 617-573-3632